RecruitingPhase 2NCT07089992
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Studying Epithelioid sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Robert Maki, MD, MPH, MD, PhDMemorial Sloan Kettering Cancer Center
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (6)
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07089992 on ClinicalTrials.govOther trials for Epithelioid sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT04390737Evaluate the Safety and Clinical Activity of HH2853Haihe Biopharma Co., Ltd.
- RECRUITINGNCT04300257Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma CareKantonsspital Winterthur KSW
- RECRUITINGNCT03099681An Observational Study on Epithelioid SarcomaItalian Sarcoma Group